COVID-19. Этиология, патогенез, диагностика и лечение

COVID-19. Этиология, патогенез, диагностика и лечение

Автор: Баклаушев Владимир Павлович, Кулемзин Сергей Викторович, Горчаков Андрей Александрович, Лесняк Виктор Николаевич, Юсубалиева Гаухар Маратовна, Сотникова Анна Геннадиевна

Журнал: Клиническая практика @clinpractice

Рубрика: Срочно в номер

Статья в выпуске: 1 т.11, 2020 года.

Бесплатный доступ

Резюме: COVID-19 (от англ. Coronavirus disease 2019) - новое эпидемическое инфекционное заболевание, характеризующееся сравнительно высокой контагиозностью и вероятностью развития жизнеугрожающих осложнений в виде острого респираторного дистресс-синдрома, острой дыхательной и полиорганной недостаточности. Возбудитель заболевания - оболочечный зоонозный РНК-вирус SARS-CoV-2 - относится к семейству Coronaviridae, роду Betacoronavirus, как и известные ранее вирусы SARS-CoV и MERS-CoV, которые вызывают тяжелый острый респираторный синдром и ближневосточный респираторный синдром соответственно. Эпидемия COVID-19 быстро распространилась по всему миру и в настоящее время охватывает 213 стран, в которых зарегистрировано более 1,6 млн заболевших, из которых на данный момент умерло более 90 000 человек. Постановлением Правительства Российской Федерации SARS-CoV-2 включен в перечень заболеваний, представляющих опасность для окружающих наряду с особо опасными инфекциями. Вирус передается воздушно-капельным, воздушно-пылевым и контактным путями, поэтому для защиты медперсонала необходимо применение индивидуальных защитных костюмов и принадлежностей с защитой дыхательных путей и глаз, проведение дезинфекции рук и поверхностей, как при работе с микроорганизмами I-II группы патогенности...

Еще

Коронавирус, этиопатогенез, кт-терапия, мск, nk-клетки

Короткий адрес: https://sciup.org/143170838

IDR: 143170838   |   DOI: 10.17816/clinpract26339

Список литературы COVID-19. Этиология, патогенез, диагностика и лечение

  • Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536-544. DOI: 10.1038/s41564-020-0695-z
  • Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733. DOI: 10.1056/NEJMoa2001017
  • Coronavirus disease (COVID-19) Pandemic. Avalable from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
  • Yang Y, Yang MH, Shen CG, et al. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019- nCoV infections. medRxiv. 2020; published online Feb 17. DOI: 10.1101/2020.02.11.20021493
  • Временные методические рекомендации Минздрава России: Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19), версия 5 (08.04.2020). - М.: Минздрав РФ, 2020. - 122 с.
  • Handbook of COVID-19 prevention and treatment. The First Affiliated Hospital, Zhejiang University School of Medicine, 2020. Available from: https://covid-19.alibabacloud.com.
  • COVID-19: Interim Guidance on Management Pending Empirical Evidence. From an American Thoracic Society-led International Task Force. Avalable from: https://www.thoracic.org/professionals/clinical-resources/disease-related-resources/covid-19-guidance.pdf.
  • Online resource. Avalable from: https://clinicaltrials.gov/ct2/results?cond=COVID-19.
  • Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection. ClinicalTrials.gov; 2020. Identifier: NCT04283461.
  • Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199-1207.
  • DOI: 10.1056/NEJMoa2001316
  • Постановление Правительства РФ от 31 января 2020 г. № ٦٦ "О внесении изменения в перечень заболеваний, представляющих опасность для окружающих". Доступно по: https://base.garant.ru/73492109/. Ссылка активна на 20.03.2020.
  • Wang K, Chen W, Zhou YS, et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. bioRxiv. 2020.
  • DOI: 10.1101/2020.03.14.988345
  • Bian H, Zheng ZH, Wei D, et al. Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial. bioRxiv. 2020.
  • DOI: 10.1101/2020.03.21.20040691
  • Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020.
  • DOI: 10.1016/j.cell.2020.02.052
  • Tisoncik JR, Korth M, Simmons CP, et al. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012;76(1):16-32.
  • DOI: 10.1128/MMBR.05015-11
  • Zhang C, Wu Z, Li JW, et al. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020:105954.
  • DOI: 10.1016/j.ijantimicag.2020.105954
  • Da Silva AM, Kaulbach HC, Chuidian FS, et al. Shock and multiple-organ dysfunction after self-administration of salmonella endotoxin. N Engl J Med. 1993;328:1457-1460.
  • DOI: 10.1056/NEJM199305203282005
  • Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018-1028.
  • DOI: 10.1056/NEJMoa063842
  • Singh N, Hofmann TJ, Gershenson Z, et al. Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function. Cytotherapy. 2017;19(7):867-880.
  • DOI: 10.1016/j.jcyt.2017.04.001
  • Giavridis T, van der Stegen SJ, Eyquem J, et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24(6):731-738.
  • DOI: 10.1038/s41591-018-0041-7
  • Sterner RM, Sakemura R, Cox MJ, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019;133(7):697-709.
  • DOI: 10.1182/blood-2018-10-881722
  • Channappanavar R, Fehr AR, Vijay R, et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe. 2016;19(2):181-193.
  • DOI: 10.1016/j.chom.2016.01.007
  • Yang Y, Shen C, Li J, et al. Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome. medRxiv. 2020.
  • DOI: 10.1101/2020.03.02.20029975
  • Zhang B, Zhou X, Zhu C, et al. Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19. medRxiv. 2020.
  • DOI: 10.1101/2020.03.12.20035048
  • Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;15;395(10223):497-506.
  • DOI: 10.1016/S0140-6736(20)30183-5
  • Cao Y, Liu X, Xiong L, Cai K. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: a systematic review and meta-analysis. J Med Virol. 2020.
  • DOI: 10.1002/jmv.25822
  • Ling W. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect. 2020.
  • DOI: 10.1016/j.medmal.2020.03.007
  • Soldati G, Smargiassi A, Inchingolo R, et al. Proposal for international standardization of the use of lung ultrasound for COVID-19 patients; a simple, quantitative, reproducible method. J Ultrasound Med. 2020.
  • DOI: 10.1002/jum.15285
  • Cao B, Wang Y, Wen D, et al. A Trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020.
  • DOI: 10.1056/NEJMoa2001282
  • Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020:105949.
  • DOI: 10.1016/j.ijantimicag.2020.105949
  • Colson P, Rolain JM, Lagier JC, et al. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020 Mar 4:105932.
  • DOI: 10.1016/j.ijantimicag.2020.105932
  • Darren D, Gates S, Morris T. Statistical review of Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial (Version 1.1). Zenodo. 2020.
  • DOI: 10.5281/zenodo.3725560
  • Study of open label losartan in COVID-19. ClinicalTrials.gov; 2020. Identifier: NCT04335123.
  • Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treatment for patients with COVID-19. ClinicalTrials.gov; 2020. Identifier: NCT04287686.
  • DOI: 10.31525/ct1-nct04287686
  • Caly L, Druce JD, Catton MG, et al. The FDA-approved Drug Ivermectin inhibits the replication of SARS-1 CoV-2 in vitro. Antiviral Research. 2020.
  • DOI: 10.1016/j.antiviral.2020.104787
  • Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19. ClinicalTrials.gov; 2020. Identifier: NCT04315298.
  • Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients. ClinicalTrials.gov; 2020. Identifier: NCT04321993.
  • Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19. ClinicalTrials.gov; 2020. Identifier: NCT04315298.
  • Treatment of COVID-19 Patients With Anti-interleukin Drugs (COV-AID). ClinicalTrials.gov; 2020. Identifier: NCT04330638.
  • A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). Chinese Clinical trial registry: ChiCTR2000029765. ChiCTR; 2020.
  • Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection. ClinicalTrials.gov; 2020. Identifier: NCT04324021.
  • A clinical study for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19). Chinese Clinical trial registry: ChiCTR2000030089. ChiCTR; 2020.
  • Izana starts compassionate use study of potential Covid-19 drug. Available from: https://www.clinicaltrialsarena.com/news/izana-namilumab-covid-19-study/.
  • Novant Health operates a fully integrated healthcare system throughout four states. Available from: https://www.cytodyn.com/newsroom/press-releases/detail/411/novant-health-initiates-phase-2-covid-19-trial-with.
  • Mehta Р, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020.
  • DOI: 10.1016/S0140-6736(20)30628-0
  • Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet. 2020.
  • DOI: 10.1016/S1473-3099(20)30132-8
  • Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. J Microbiol, Immunol Infect. 2020.
  • DOI: 10.1016/j.jmii.2020.03.005
  • Safety and Efficacy of Baricitinib for COVID-19. ClinicalTrials.gov; 2020. Identifier: NCT04340232.
  • Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study. (BARI-COVID). ClinicalTrials.gov; 2020. Identifier: NCT04320277.
  • Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia. ClinicalTrials.gov; 2020. Identifier: NCT04331665.
  • Praveen D, Chowdary PR, Aanandhi MV. Baricitinib - a januase kinase inhibitor - not an ideal option for management of COVID 19. Int J Antimicrob Agents. 2020 Apr 4 [Online ahead of print]
  • DOI: 10.1016/j.ijantimicag.2020.105967
  • Zhang R, Wang X, Ni L, et al. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci. 2020 Mar 23:117583.
  • DOI: 10.1016/j.lfs.2020.117583
  • Zhang B, Liu S, Tan T, et al. Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. Chest. 2020. pii: S0012-3692(20)30571-7.
  • DOI: 10.1016/j.chest.2020.03.039
  • Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020 Apr 6. pii: 202004168.
  • DOI: 10.1073/pnas.2004168117
  • Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020 Mar 27.
  • DOI: 10.1001/jama.2020.4783
  • Hyperimmune plasma for critical patients with COVID-19 (COV19-PLASMA). ClinicalTrials.gov; 2020. Identifier: NCT04321421.
  • Convalescent plasma to limit coronavirus associated complications. ClinicalTrials.gov; 2020. Identifier: NCT04325672.
  • Anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of COVID-19. ClinicalTrials.gov; 2020. Identifier: NCT04292340.
  • DOI: 10.31525/ct1-nct04292340
  • Safety in convalescent plasma transfusion to COVID-19. ClinicalTrials.gov; 2020. Identifier: NCT04333355.
  • Online resource. Available from: https://clinicaltrials.gov/ct2/results?cond=COVID-19%2C++Convalescent+Plasma+&term=&cntry=&state=&city=&dist=.
  • Jiang S, Hillyer C, Du L, et al. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Science Society. 2020.
  • DOI: 10.1016/j.it.2020.03.007
  • Горшкова Е.Н., Василенко Е.А., Тиллиб С.В., Астраханцева И.В. Однодоменные антитела и биоинженерные препараты на их основе: новые возможности для диагностики и терапии // Медицинская иммунология. - 2016. - Т.18. - №6. - С. 505-520.
  • DOI: 10.15789/1563-0625-2016-6-505-520
  • Krah S, Schröter C, Zielonka S, Empting M, Valldorf B, Kolmar H. Single-domain antibodies for biomedical applications. Immunopharmacol Immunotoxicol. 2016;38(1):21-8.
  • Wrapp D, de Vlieger D, Corbett KS, et al. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-domain Camelid Antibodies. medRxiv. 2020.
  • DOI: 10.1101/2020.03.26.010165
  • Lafaye P, Li T. Use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases. Comp Immunol Microbiol Infect Dis. 2018;60:17-22.
  • Lei C, Fu W, Qian K, et al. Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig. BioRxiv. 2020.
  • DOI: 10.1101/2020.02.01.929976
  • Toonkel RL, Hare JM, Matthay MA, Glassberg MK. Mesenchymal stem cells and idiopathic pulmonary fibrosis: potential for clinical testing. Am J Respir Crit Care Med. 2013;188(2):133-140.
  • DOI: 10.1164/rccm.201207-1204PP
  • Averyanov A, Koroleva I, Konoplyannikov M, et al. First-in-human high-cumulative-dose stem cell therapy in idiopathic pulmonary fibrosis with rapid lung function decline. Stem Cells Transl Med. 2020;9(1):6-16.
  • DOI: 10.1002/sctm.19-0037
  • Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13(4):392-402.
  • DOI: 10.1016/j.stem.2013.09.006
  • Wilson JG, Liu KD, Zhuo H, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med. 2015;3(1):24-32.
  • DOI: 10.1016/S2213-2600(14)70291-7
  • Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216-228.
  • DOI: 10.14336/AD.2020.0228
  • Stem cell educator therapy treat the viral inflammation caused by Severe Acute Respiratory Syndrome Coronavirus 2. ClinicalTrials.gov; 2020. Identifier: NCT04299152.
  • DOI: 10.31525/ct1-nct04299152
  • Cell therapy using umbilical cord-derived mesenchymal stromal cells in SARS-CoV-2-related ARDS (STROMA-CoV2). ClinicalTrials.gov; 2020. Identifier: NCT04333368.
  • Sorrento to provide manufacturing support to celularity as CYNK-001 NK cell trial for COVID-19 begins enrolling patients [news release]. San Diego, CA.; 2020. Available from: globenewswire.com/news-release/2020/04/02/2010998/0/en/SORRENTO-TO-PROVIDE-MANUFACTURING-SUPPORT-TO-CELULARITY-AS-CYNK-001-NK-CELL-TRIAL-FOR-COVID-19-BEGINS-ENROLLING-PATIENTS.html.
  • Xconomy National. Celularity to test natural killer cell therapy for cancer against COVID. Xconomy National website; 2020. Available from: xconomy.com/national/2020/04/02/celularity-to-test-natural-killer-cell-therapy-for-cancer-against-covid/.
  • A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19. ClinicalTrials.gov; 2020. Identifier: NCT04324996.
Еще
Статья научная
SciUp 2024 © 2024 ©